Pfizer filed an antitrust lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for ...

The lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by ...

(Reuters) -Pfizer Inc said on Monday it has filed a second lawsuit against Metsera and its controlling shareholders, as well ...

The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks. Read more here.

Denmark's Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any antitrust issues.

After filing one lawsuit to try to block Novo Nordisk's $9 billion effort to trump the takeover, Pfizer has returned to the courts with another, accusing Metsera and Novo Nordisk of anticompetitive ...

Pfizer's lawsuits target Metsera, its directors, and Novo Nordisk for breach of contract and antitrust violations, focusing on Novo Nordisk's acquisition proposal. The first lawsuit claims Novo ...